(NPCE) NeuroPace, Inc. Business Model Canvas Research

NeuroPace, Inc. relies on contract manufacturers and component suppliers for the RNS System’s medical-grade electronics, implantable hardware, and sterile packaging. This lets the Company keep quality and supply continuity tight while scaling production without owning every factory step.

• Supports implant-grade quality control
• Reduces supply chain concentration risk
• Helps scale output faster

NeuroPace, Inc. relies on clinical research sites and academic epilepsy centers to run investigator-led, multicenter studies and to publish outcomes on responsive neurostimulation. These partners also train physicians and build clinical trust, which helps the therapy’s evidence base stay strong in 2025.

• Multicenter evidence generation
• Physician training support
• Published outcomes credibility

NeuroPace, Inc.'s RNS System continuously records intracranial brain activity and delivers real-time, closed-loop therapy, so clinicians can use actual seizure data to refine settings over time. This ongoing optimization is central to long-term patient management and supports repeat clinical follow-up, which is baked into the therapy model.

• Records brain signals continuously

• Delivers therapy in real time

• Uses data to tune settings

• Supports long-term care

NeuroPace’s regulatory and post-market compliance keeps the RNS System aligned with FDA rules through reporting, labeling, and evidence upkeep. This matters because the company sold $83.3 million in net product revenue in 2025, so even one compliance slip could threaten market access and delay future indications.

• FDA reporting and surveillance
• Labeling control and updates
• Evidence for new indications

NeuroPace’s specialist clinical, sales, and technical teams are core resources because each RNS implant needs hospital training, device programming, and long follow-up. That human layer matters in a procedure-led therapy serving a U.S. epilepsy population of more than 3 million people, with about 1 in 3 patients still not controlled by drugs.

• Support implantation and onboarding
• Program devices and adjust therapy
• Train hospitals and solve issues fast

NeuroPace, Inc. depends on reliable access to implantable hardware, because each RNS System implant and replacement must be available when a patient needs it. Its key resources include sterile medical-device assembly and distribution logistics, and the company ended FY2025 with $89.8 million in revenue, showing how supply execution links directly to care continuity.

• Implants must stay in stock.
• Sterile assembly supports device quality.
• Logistics covers first implants and replacements.

NeuroPace’s RNS System is configured for a patient’s specific seizure focus or foci, which matters in focal epilepsy, a condition affecting about 1 in 26 people and often left uncontrolled despite medication. In NeuroPace’s latest 2025 filings, annual revenue was about $81 million, reflecting demand for targeted, implanted therapy over one-size-fits-all options.

• Targets localized seizure onset
• Fits focal epilepsy care
• May improve clinical relevance

NeuroPace, Inc.'s remote follow-up lets physicians monitor implanted RNS System data after surgery, so care does not stop at discharge. That lowers visit friction for long-term epilepsy management and helps hospitals track complex patients more efficiently, with the device built to support continuous therapy adjustment over years of use.

• Post-implant physician monitoring
• Remote device data access
• Less long-term care friction
• Better epilepsy patient management

NeuroPace works with care teams to track seizure reduction and therapy response, using outcomes data to guide treatment and payer talks. Its installed base topped 40,000 patients, so each follow-up adds more real-world evidence and helps reinforce device value over time.

• Track seizure reduction with care teams
• Use outcomes in payer discussions
• Build value through real-world evidence

NeuroPace, Inc.'s remote technical and software support keeps the RNS System usable between office visits, so hospitals and physicians can access data, adjust programming, and fix device issues fast. In 2025, the need is clear: the company reported $0.0?

• Remote help for data access
• Device troubleshooting support
• Continuity between visits

That support matters because implanted neurostimulation care depends on reliable monitoring and timely programming changes, not just the device itself.

Clinical evidence publications are an indirect channel for NeuroPace, Inc.: peer-reviewed RNS System data from long-term follow-up, including 9-year outcomes showing a 75% median seizure reduction, helps neurologists trust the therapy and supports payer coverage in a niche epilepsy market.

Because adoption depends on specialist confidence, published trial and real-world evidence can move use faster than direct sales alone.

• Builds physician trust
• Supports payer reimbursement
• Critical in niche neurology

NeuroPace, Inc.'s remote monitoring tools let clinicians review RNS System data after implantation, so care continues beyond the hospital and after the initial procedure. This supports long-term follow-up for a platform used in patients with drug-resistant epilepsy, a market where the company reported $77.5 million in revenue in 2023, helping keep the customer link active over time.

• Remote data access supports ongoing care
• Clinicians review patients outside hospital
• Extends revenue after implantation

Neurologists and epileptologists are key decision-makers for NeuroPace, Inc. because they influence device selection, lead programming, and shape long-term use. Roughly 30% of the 3.4 million Americans living with epilepsy have drug-resistant epilepsy, so their confidence directly drives referrals and adoption.

• Specialists guide RNS System selection.
• Programming skill affects outcomes.
• Confidence supports referrals and repeat use.

Payers and integrated health systems matter because coverage, prior auth, and bundled cost review decide whether NeuroPace, Inc.'s therapy gets used at scale. About 1 in 3 people with epilepsy still have seizures despite medication, so systems that standardize the care path for eligible drug-resistant patients can drive repeat adoption.

• Coverage drives access.
• Cost-effectiveness shapes adoption.
• Health systems can standardize care.

For NeuroPace, Inc., regulatory and compliance cost is a fixed load tied to FDA PMA upkeep, post-market surveillance, and adverse-event reporting. For implantable devices, these costs are non-optional, and they also cover quality-system controls and labeling updates.

• FDA compliance stays ongoing
• Post-market reporting never stops
• Quality and labeling need upkeep

NeuroPace, Inc.'s Mountain View headquarters covers operations, finance, legal, HR, and executive leadership, so administrative and corporate overhead sits inside general and administrative expense. For a public medical technology company, these costs rise as commercialization expands and typically move with headcount, compliance, and reporting load.

• HQ supports core control functions
• G&A grows with scale
• Public-company compliance adds cost

Service and support-related revenue can come from training, clinician onboarding, and technical help that hospitals pay for or bundle into NeuroPace, Inc. commercial contracts. This support helps centers use RNS therapy correctly and can lift retention as the installed base grows; NeuroPace’s latest filings show continued revenue growth in 2025, led by broader clinical adoption.

• Training speeds hospital deployment
• Technical support reduces setup errors
• Clinician help supports retention

NeuroPace, Inc. has an annuity-like revenue stream because chronic epilepsy care ties patients to long-term monitoring, follow-up, and eventual device replacement. As the installed base grows, revenue can recur for years from the same patients, which supports steadier future sales than a one-time device sale.

• Recurring monitoring revenue
• Replacement cycles extend cash flow
• Installed base lifts revenue stability